FDA Approves New Treatment for Thyroid Eye Disease - Top-Institutions - MDSpire

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, TX

    Key Differentiators

    • Ophthalmology

  • #2

    University of Minnesota Medical School
    University of Minnesota Medical School

    Minneapolis, MN

    Key Differentiators

    • Ophthalmology

  • #3

    Center of Thyroid Eye Disease
    Center of Thyroid Eye Disease

    Minneapolis, MN

    Key Differentiators

    • Ophthalmology

  • #4

    New York Eye and Ear Infirmary of Mount Sinai
    New York Eye and Ear Infirmary of Mount Sinai

    New York, NY

    Key Differentiators

    • Ophthalmology

  • #5

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, NY

    Key Differentiators

    • Ophthalmology

Original Source(s)

FDA Approves New Treatment for Thyroid Eye Disease

  • by Kathryn Wighton

  • June 29, 2026

Related Content

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Do Revisions in Rotator Cuff Repair Decline With GLP-1 Use?

Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.